Phase 4 N=395 Nephropathy In Type 2 Diabetes and Cardio-renal Events
Diabetic Nephropathy
Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=83 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline
Phase 3 N=170 Renoprotection in Early Diabetic Nephropathy in Pima Indians
Diabetic Nephropathy
Primary: Number of Participants With Decline in GFR — 2; 2; 1; 4 participants
Phase 2 N=60 Study of LY3016859 in Participants With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Part B:Change From Baseline in Proteinuria — 1.5; -0.4; 0.1; 0.7 grams per 12 hour (g/12 hour) — p=0.0449
Phase 2 N=53 Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
Chronic Kidney Diseases · Proteinuria
Primary: Change in 24-hr Proteinuria With Dapagliflozin for Six Weeks Relative to Placebo in Patients With Non-diabetic Kidney Disease and Proteinuria 500 mg/Day on Stable…
Phase 2 N=78 N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Diabetic Nephropathy · Proteinuria · Oxidative Stress
Primary: Change From Baseline in Urinary Albumin Excretion — 50.5; -28.13; -4.5; 96.6 mg/g
N/A N=1,819 Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
Hypertension
Primary: Change in Blood Pressure — -1; -2; -2; -2 mmHg
Phase 4 N=44 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
Diabetes Mellitus, Type 2 · Diabetic Nephropathies
Primary: Glomerular Filtration Rate (GFR) in ml/Min — 104; 109 ml/min
N/A N=136 A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)
Hypertension
Primary: Number of Participants With Macroalbuminuria After 6 Months of Treatment — 7; 6 participants
Phase 2 N=256 A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Diabetic Nephropathies
Primary: Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12 — 195.130; 182.378; 9.072; -6.539 mg/mmol — p=0.9889
N/A N=28 Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr
Phase 2 N=156 A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs — 24; 21; 22; 6 Participants
Phase 2 N=34 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Diabetic Nephropathy
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change
Phase 4 N=21 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI — 22.04 1/ms
Phase 4 N=34 Glargine Versus NPH in Patients With Chronic Kidney Disease
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045
N/A N=36 Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change in Proteinuria — -34; -133 mg/g creatinine — p=0.04
Phase 2 N=599 A Phase 2b Diabetic Kidney Disease Study
Diabetic Kidney Disease
Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338
N/A N=142 Five, Plus Nuts and Beans for Kidneys
Chronic Kidney Disease · Hypertension
Primary: Change in Urinary Albumin Excretion From Baseline to 4 Months — -28.6; -5.6 mg/g — p=0.17
Phase 3 N=308 Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104 — 18.2; 29.5 Percentage of Participants
Phase 4 N=1,143 Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
Hypertension
Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8 — -15.3; -11.5 mmHg
Phase 4 N=84 Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
SLE · Lupus Nephritis · SGLT2 Inhibitors
Primary: Effect of Dapagliflozin Compared to Placebo on Renal Function After One Year — 128; 114; 115.7; 100.3 mL/min/1.73 m²
N/A N=23,357 A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Difference in Mean CKD Register Patient eGFRs Between Groups After 3.5 Years of Study — -2.00; -2.29 mean average eGFR change/mL/min/1.73 m^2
Phase 2 N=136 Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Albuminuria Absolute Value and Ratio to Baseline by Study Visit and Treatment Group — 705.72; 696.30; 758.22; 705.29 mg/g — p=1.000
N/A N=31 Diet and Hypertension Management in African Americans With Chronic Kidney Disease
Chronic Kidney Diseases · High Blood Pressure
Primary: Number of Group Counseling Sessions Attended by Participants Randomized to the Treatment Arm — 8.9 sessions per participant
Phase 4 N=72 Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Diabetes Mellitus, Type 2
Primary: GFR (Glomerular Filtration Rate) Change After Treatment — 22; 1; 8; 0 ml/min/1.73m^2
N/A N=32 Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis
Arterial Hypertension · Hemodialysis
Primary: Cardiac Output — 3.9; 4.10; 4.6 L/min
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
Phase 3 N=251 Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 2 N=160 Chlorthalidone in Chronic Kidney Disease
Renal Insufficiency, Chronic · Hypertension
Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg
Phase 4 N=28 Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g